What is the relationship between Tremelimumab/Tremelimumab and Tremelimumab?

In the communication between domestic patients and doctors, the problem of different translations of temsilimumab often arises. In fact, Tremelimumab is a single anti-CTLA-4 monoclonal antibody drug. However, since it has not yet been officially launched in mainland China, there is no unified standard for its Chinese name. In different medical information and drug descriptions, you can see that it is called "temelelimumab", "tremelimumab" or "tremelimumab", etc. These names all correspond to the same drug.

The real clinical value of this drug lies in its combination with durvalumab (Durvalumab). For unresectable hepatocellular carcinoma (uHCC), traditional treatment methods such as surgery or local ablation are often limited and the prognosis is poor. Temtumumab prevents T cells from premature exhaustion by blocking the CTLA-4 signaling pathway, while durvalumab further enhances immune activity by inhibiting the PD-L1/PD-1 pathway. This "double immunity" strategy has shown potential to improve patient survival in the clinic. On the other hand, in the field of metastatic non-small cell lung cancer (NSCLC), this combination regimen combined with platinum-based chemotherapy shows a new treatment idea for patients without EGFR sensitive mutations or ALK gene rearrangements.

From the perspective of drug development, there is no essential difference between temtumumab and tremelimumab, only the difference in language translation and transliteration. Since the drug has not yet entered the mainland market, there is a certain degree of confusion about its name among the public and the media, which has also caused confusion to some patients. In the future, as the drug officially enters the mainland Chinese market, the State Food and Drug Administration will unify its Chinese generic names, and this problem will be solved.

Overall,Tremelimumab, whether it is called tremelimumab or tremelimumab, has the same core mechanism of action and indications. As an immune checkpoint inhibitor, its combined application with durvalumab represents an important development in the field of immunotherapy in the treatment of liver cancer and lung cancer.

Reference: https://www.drugs.com/mtm/tremelimumab.html